CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study

Journal of the American Academy of Dermatology

Volumn 49, Issue 5, 2003, Pages 816-825

  Gottlieb, Alice B ^a   Casale, Thomas B ^b   Frankel, Ellen ^c   Goffe, Bernard ^d   Lowe, Nicholas ^e   Ochs, Hans D ^f   Roberts, Janet L ^g   Washenik, Ken ^g   Vaishnaw, Akshay K ^h   Gordon, Kenneth B ⁱ  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c Clinical Partners   (United States)

^d Minor and James Medical   (United States)

^e Clinical Research Specialists   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g NW Cutaneous Research Specialists ^*

^h BIOGEN   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BACTERIAL ANTIGEN; CD4 ANTIGEN; IMMUNOGLOBULIN G; TETANUS ANTIBODY; TETANUS TOXIN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; INFECTION; INFECTION PREVENTION; MALE; MEMORY CELL; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

EID: 0142182716     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)01836-X     Document Type: Article

References (42)

1. 2+ T cells is independent of cell activation. Cell Adhes Commun 1999;7:267-79.
2. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988; 140:1401-7.
3. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-81.
4. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
5. +) in both normal and diseased human skin. Arch Dermatol Res 1989;281:24-30.
6. Friedrich M, Krammig S, Henze M, Döcke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000;292:519-21.
7. + perivascular dendritic cells. J Invest Dermatol 1991;96:333-40.
8. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
9. Delves PJ, Roitt IM. The immune system: first of two parts. N Engl J Med 2000;343:37-49.
10. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998;16:201-23.
11. Abbas AK, Lichtman AH, Pober JS, editors. Cellular and molecular immunology. 4th ed. Philadelphia: WB Saunders; 2000.
12. Pyun KH, Ochs HD, Wedgwood RJ, Xiqiang Y, Heller SR, Reimer CB. Human antibody responses to bacteriophage φX174: sequential induction of IgM and IgG subclass antibody. Clin Immunol Immunopathol 1989;51:252-63.
13. + T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 2000;182:435-41.
14. + lymphocytes. AIDS 1994;8:469-76.
15. Rubinstein A, Mizrachi Y, Bernstein L, Shliozberg J, Golodner M, Liu G-Q, et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage φX174 in asymptomatic HIV-1 infected patients. AIDS 2000;14:F55-62.
16. Sullivan JL, Ochs HD, Schiffman G, Hammerschlag MR, Miser J, Vichinsky E, et al. Immune response after splenectomy. Lancet 1978;1:178-81.
17. Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. AIDS 2000;14:11-21.
18. Nonoyama S, Etzioni A, Toru H, Ruggerie DP, Lewis D, Pollack S, et al. Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency. Eur J Immunol 1998;28:589-98.
19. Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage φX 174 in immunodeficiency diseases. J Clin Invest 1971;50:2559-68.
20. Ochs HD, Nonoyama S, Farrington ML, Fischer SH, Aruffo A. The role of adhesion molecules in the regulation of antibody responses. Semin Hematol 1993;30:72-9.
21. Ochs HD, Nonoyama S, Zhu Q, Farrington M, Wedgwood RJ. Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol Immunopathol 1993; 67(Suppl):S33-40.
22. Wedgwood RJ, Ochs HD, Davis SD. The recognition and classification of immunodeficiency diseases with bacteriophage φX174. In: Bergsma DR, editor. Immunodeficiency in man and animals: March of Dimes Birth Defects Original Article Series. Vol 11. Sunderland (MA): Sinauer; 1975. p. 331-8.
23. Christophers E, Bourcier M, Griffiths C, Guenther L, Langley R, Lebwohl M, et al. Study design and demographics of a randomized, double-blind, placebo-controlled phase 3 dose-comparison study to evaluate weekly intramuscular administration of alefacept in chronic plaque psoriasis [abstract P24-47]. JEADV 2001;15:29.
24. Lebwohl M, Bissonnette R, Ellis C, Gordon K, Gottlieb A, Gulliver W, et al. Study design and demographics of a randomized, double-blind, placebo-controlled phase 3 study to evaluate weekly IV bolus administration of alefacept in chronic plaque psoriasis [abstract P24-46]. JEADV 2001;15:248-9.
25. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410:101-5.
26. Von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med 2000;343:1020-34.
27. - human T cells. J Immunol 2000;165:1910-7.
28. + T cells. J Exp Med 1997;186:1407-18.
29. - cells are induced by antigen and evolve through extensive rounds of division. Int Immunol 1999;11:1027-33.
30. Dumont-Girard F, Roux E, van Lier RA, Hale G, Helg C, Chapuis B, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998;92:4464-71.
31. Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90:3789-98.
32. Mclean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci U S A 1995;92: 3707-11.
33. Michie CA, McLean A, Alcock C, Beverley PC. Lifespans of human lymphocyte subsets defined by CD45 isoforms. Nature 1992;360:264-5.
34. Björkholm B, Hagberg L, Sundbeck G, Granström M. Booster effect of low doses of tetanus toxoid in elderly vaccinees. Eur J Microbiol Infect Dis 2000;19:195-9.
35. Janoff EN, Hardy WD, Smith PD, Wahl SM. Humoral recall responses in HIV infection: levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991;147:2130-5.
36. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991; 84:185-9.
37. Trinca JC. Antibody response to successive booster doses of tetanus toxoid in adults. Infect Immun 1974;10:1-5.
38. Trinca JC. Combined diphtheria-tetanus immunization of adults. Med J Aust 1975;2:543-6.
39. + T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1197-203.
40. Kroon FP, van Tol MJD, Jol-van der Zijde CM, van Furth R, van Dissel JT. Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin Diagn Lab Immunol 1999;6:352-5.
41. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103: 1243-52.
42. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.